Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Size, Share & Trends Analysis Report By Service Type (Drug Development Services, Pharmaceutical Manufacturing Services, Biologics Manufacturing Services, Packaging & Labelling Services, Fill-finish Services, Others), By Research Phase (Pre-clinical, Phase I, Phase II, Phase III, Phase IV), By End-User (Big Pharmaceutical Companies, Small & Mid-Sized Pharmaceutical Companies, Generic Pharmaceutical Companies, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Pharmaceutical Contract Development and Manufacturing Organization (cdmo) Market Size

The global pharmaceutical contract development and manufacturing organization market size was valued at USD 214.56 billion in 2025 and is projected to grow from USD 229.15 billion in 2026 to USD 387.87 billion by 2034, registering a CAGR of 6.8% during the forecast period from 2026 to 2034. North America dominated the pharmaceutical contract development and manufacturing organization market with a market share of 38.2% in 2025.

Advanced manufacturing techniques and processes are set to drive growth in the global pharmaceutical CDMO market. CMOs are expected to enhance their manufacturing efficiency by adopting operational strategies like continuous manufacturing, which minimizes waste and reduces costs. The rise of small and mid-sized pharmaceutical firms, responsible for a growing share of new drug approvals but often lacking manufacturing capacity, is likely to propel CMOs to implement these new technologies.

Market growth is also fueled by the increasing complexity of drug development and the demand for cost-effective solutions. For instance, the WHO's 2022 study estimated that the cost to develop a new drug ranges from approximately USD 43.4 million to USD 4.2 billion. By outsourcing to CDMOs, companies can access specialized expertise and advanced manufacturing capabilities without incurring high overhead costs.

This approach allows them to concentrate on core activities, reduce financial risks, and enhance operational flexibility, further driving the growth of the CDMO market in the coming years.

Pharmaceutical Contract Development and Manufacturing Organization (cdmo) Market Trends

Increasing Demand for Biopharmaceuticals to Treat Rare Diseases

The growing demand for biopharmaceuticals aimed at treating rare diseases is a significant market trend in the pharmaceutical CDMO market. Companies are increasingly focusing on specialized manufacturing capabilities, particularly in areas like exosome-based therapies. As these firms innovate and develop new treatments, they turn to CDMOs for essential services such as formulation development and manufacturing.

This reliance allows pharmaceutical companies to streamline their research and development processes, boost productivity, and accelerate drug development timelines, all while reducing costs and mitigating risks.

• For instance, in January 2024, EXO Biologics SA launched ExoXpert, a CDMO for the GMP production of exosomes, leveraging its proprietary ExoPulse manufacturing platform to meet the rising demand for exosomes to treat rare diseases with high unmet medical needs.

Shift towards sustainable practices

The pharmaceutical industry is increasingly emphasizing sustainability. CDMOs are adopting green chemistry practices and sustainable manufacturing processes to minimize their environmental impact.

• For instance, in May 2024, WuXi AppTec's Singapore facility aims to embrace industry-leading green chemistry technology initiatives.

Thus, this shift supports environmental goals, enhances operational efficiency, and aligns with the growing demand for eco-friendly drug development and manufacturing solutions.Bottom of Form

Market Growth Factors

Rising Drug Development Complexity

The increasing complexity of drug development processes and regulatory requirements is compelling pharmaceutical companies to turn to contract development and manufacturing organizations (CDMOs) for expertise. As the pharmaceutical landscape evolves, there is a growing need for specialized knowledge to navigate intricate regulations and advanced manufacturing techniques.

Collaborating with CDMOs allows pharmaceutical firms to access cutting-edge technologies, ensure regulatory compliance, and streamline development timelines. This partnership not only reduces risks associated with in-house manufacturing but also enhances the efficiency of bringing new therapies to market, making CDMOs essential in the drug development process.

• For instance, the costs of in-house drug development are significant, particularly for small and mid-sized pharmaceutical firms that face significant financial pressures from technology investments and infrastructure maintenance.

Expansion of Clinical Trials

The rising number of clinical trials is driving the demand for pharmaceutical CDMO services, largely due to the increasing complexity of drug development. Pharmaceutical companies often lack the resources and expertise needed for manufacturing and regulatory compliance, making CDMOs essential partners.

Moreover, they offer specialized services such as formulation development, clinical trial material production, and quality assurance, enabling drug developers to accelerate timelines, reduce costs, and mitigate risks. This growing reliance on CDMOs contributes significantly to market growth.

• For instance, in 2023, ClinicalTrials.gov reported approximately 477,237 registered clinical studies, highlighting robust growth in clinical research. This surge underscores the essential role of CDMOs as partners, offering critical support in drug development processes.

Market Restraining Factors

Regulatory Compliance Challenges

The failure to comply with regulatory standards and produce quality pharmaceuticals can severely impact a CDMO's business and brand reputation. Adherence to regulations is crucial in the pharmaceutical industry, especially since CDMOs manufacture drug substances and formulations under their own brand.

The medication development and clinical trial processes require extensive data submission to regulatory authorities, which poses challenges in managing this data and filing diverse formulations across different countries. These complexities increase the risk of errors in regulatory submissions and are expected to hinder the growth of CDMOs in the foreseeable future.

Market Opportunities

Harnessing Process Automation

The integration of process automation offers a transformative opportunity for pharmaceutical CDMOs, driving efficiency and reliability in production. By adopting advanced software, sensors, and PLCs, CDMOs can streamline manufacturing processes, reduce human error, and enhance overall productivity.

• For instance, Pfizer’s adoption of automated monitoring systems in its COVID-19 vaccine production exemplifies how real-time data analysis and automated quality checks can quickly identify variances and halt production when necessary.

This not only ensures product quality but also reduces operational costs and accelerates timelines, making CDMOs more competitive in the supply chain.

Segmentation Analysis

The global market is segmented into service type – CMO segment, research phase – CRO segment, and end-user.

By Service Type

The global pharmaceutical CDMO market is bifurcated into drug development services, pharmaceutical manufacturing services, biologics manufacturing services, packaging & labeling services, fill-finish services, and others.

The pharmaceutical manufacturing services segment dominates the pharmaceutical CDMO market, holding the largest market revenue. This is driven by demand for Active Pharmaceutical Ingredients (APIs) and final dosage forms (FDFs) like tablets and injectables. The rise of complex drug formulations and specialty pharmaceuticals fuels this growth, highlighting the industry's need for cost-effective, efficient manufacturing solutions.

• For instance, in May 2024, Eli Lilly announced a USD 5.3 billion investment to expand its manufacturing site in Lebanon, Indiana, bringing its total investment there to USD 9 billion. This expansion will enhance production capacity for Active Pharmaceutical Ingredients (APIs) used in its obesity and diabetes treatments, Zepbound and Mounjaro.

Request Customizationto receive a tailored report.

By the Research Phase

The global market is bifurcated into pre-clinical, phase I, phase II, phase III, and phase IV.

Phase III segment dominates the global market, holding the largest market revenue. This phase is crucial for large-scale testing of a drug's efficacy and safety, often determining regulatory approval. The significant investment and data requirements drive pharmaceutical companies to rely on CROs, making Phase III trials a key focus in drug development.

By End-User

The global market is bifurcated into big pharmaceutical companies, small & mid-sized pharmaceutical companies, generic pharmaceutical companies, and others.

The big pharmaceutical companies segment dominates the global market. These firms often struggle with the complexities of drug development and high-volume production, leading them to rely on CDMOs for specialized expertise and scalable manufacturing solutions. This partnership streamlines operations, reduces costs, and accelerates time-to-market, reinforcing the dominance of big pharmaceutical companies in the market.

Speak to an Analystto discuss market opportunities.

Regional Insights

North America: Dominant Region with A 44.2% Share in the Market

North America dominates the global pharmaceutical contract development and manufacturing organization (CDMO) market. This leadership is driven by the presence of major pharmaceutical and biotechnology manufacturers, robust funding for biopharmaceutical R&D, and increasing demand for cell and gene therapies.

Moreover, drug shortage is a significant concern in the U.S., often resulting from delays, discontinuations, and manufacturing quality issues.

• For instance, in September 2023, the U.S. FDA reported 98 medicine shortages in 2023, up from 79 in 2021, leading many pharmaceutical companies to rely on CDMOs to help mitigate these shortages. Bottom of Form

Unlock Regional Insightsto access country-level data, & regional trends.

Asia Pacific: Fastest-Growing Region with the Highest Market CAGR

The Asia Pacific region is expected to witness the fastest growth rate in the pharmaceutical CDMO market. This growth is driven by lower costs compared to the U.S. and other developed economies, alongside rising rates of chronic diseases such as diabetes and heart disease. This drives demand for the CDMO market by increasing the need for new drug development and specialized therapies.

This leads pharmaceutical companies to outsource R&D and manufacturing processes to CDMOs for their expertise and efficiency in delivering effective treatments.

• For instance, China reported over 180 million elderly citizens with chronic conditions, with significant economic impacts expected by 2030.

Additionally, the privatization of clinical trials is leading to increased research outsourcing in developing countries like China and India, as large pharmaceutical companies seek services such as clinical data management and pharmacovigilance.

List of Key and Emerging Players in Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market

• Thermo Fisher Scientific, Inc.
• Lonza Group
• WuXi Apptec
• WuXi Biologics
• AbbVie, Inc.
• Catalent, Inc.
• Samsung Biologics
• Evonik Industries AG
• FUJIFILM Holding Corporation
• Siegfried Holding AG
• Boehringer Ingelheim International
• Merck KGaA
• Almac Group
• Charles River Laboratories
• Asychem Inc.